Trial Profile

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2024 According to a Perspective Therapeutics media release, initial results from this study will be presenting at the upcoming 2024 North American Neuroendocrine Tumor Society Symposium in November.
23 Oct 2024 According to a Perspective Therapeutics media release, the company announced that it will present Interim results data presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in Hamburg, Germany, from October 19-23, 2024.
21 Aug 2024 Planned End Date changed from 31 Jan 2028 to 26 Nov 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com